Cassava Sciences shares are trading higher after the company announced MRI data suggested simufilam is not associated with amyloid-related imaging abnormalities.
Portfolio Pulse from Benzinga Newsdesk
Cassava Sciences announced that MRI data suggests its drug simufilam is not associated with amyloid-related imaging abnormalities, leading to a rise in its share price.
October 25, 2023 | 6:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cassava Sciences' stock price is likely to increase in the short term due to positive MRI data about its drug simufilam.
The announcement of positive MRI data about simufilam, a drug developed by Cassava Sciences, has led to an increase in the company's share price. This suggests that investors have reacted positively to the news, which could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100